Protocol Ledger

NCT07286032 · Phase III · RECRUITING

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

Interventional Phase III clinical trial protocol NCT07286032 sponsored by Jiangsu HengRui Medicine Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-16 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07286032
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07286032
Protocol FieldVerified Registry Value
NCT IdentifierNCT07286032
Consolidated Lead SponsorJiangsu HengRui Medicine Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2026-04-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07286032
Hospital Research SiteLocationSite Profile
Cancer and Blood Specialty ClinicLos Alamitos, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Springfield ClinicSpringfield, ILOpen Hospital Dossier ->
University of IowaIowa City, IAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI